MGMT and glioblastoma: In a large ongoing randomized phase II trial (CheckMate 548, NCT02667587), researchers are investigating nivolumab as an alternative to TMZ (both in combination with radiotherapy) in newly diagnosed GBM patients with methylated MGMT status.